

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM363345

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Therapure BioPharma Inc.		11/20/2015	CORPORATION: ONTARIO
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	MidCap Financial Trust		
<b>Street Address:</b>	c/o MidCap Financial Services, LLC, as servicer		
<b>Internal Address:</b>	7255 Woodmont Ave., Suite 200		
<b>City:</b>	Bethesda		
<b>State/Country:</b>	MARYLAND		
<b>Postal Code:</b>	20814		
<b>Entity Type:</b>	Statutory Trust: DELAWARE		
<b>PROPERTY NUMBERS Total: 7</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	86607617	DAKANSUMIN	
<b>Serial Number:</b>	86039785	PLASMACAP	
<b>Serial Number:</b>	86019802	PLASMACAP EBA	
<b>Serial Number:</b>	86019797	PLASMACAP EBA	
<b>Serial Number:</b>	86655354	THERAPURE BIOLOGICS	
<b>Serial Number:</b>	86655356	THERAPURE BIOLOGICS	
<b>Registration Number:</b>	4381498	THERAPURE BIOPHARMA	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	4044435697		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	704-343-2248		
<b>Email:</b>	lallen@mcguirewoods.com		
<b>Correspondent Name:</b>	Natalie A. Pfeiffer, Esq.		
<b>Address Line 1:</b>	McGuireWoods LLP		
<b>Address Line 2:</b>	1230 Peachtree Street, N.E., Suite 2100		
<b>Address Line 4:</b>	Atlanta, GEORGIA 30309		
<b>ATTORNEY DOCKET NUMBER:</b>	2061695-0052 THERAPURE		
<b>NAME OF SUBMITTER:</b>	Latosha E. Allen		

OP \$190.00 86607617

<b>SIGNATURE:</b>	/Latosha E. Allen/
<b>DATE SIGNED:</b>	11/23/2015
<b>Total Attachments: 13</b> source=Therapure - IP Security Agreement #page1.tif source=Therapure - IP Security Agreement #page2.tif source=Therapure - IP Security Agreement #page3.tif source=Therapure - IP Security Agreement #page4.tif source=Therapure - IP Security Agreement #page5.tif source=Therapure - IP Security Agreement #page6.tif source=Therapure - IP Security Agreement #page7.tif source=Therapure - IP Security Agreement #page8.tif source=Therapure - IP Security Agreement #page9.tif source=Therapure - IP Security Agreement #page10.tif source=Therapure - IP Security Agreement #page11.tif source=Therapure - IP Security Agreement #page12.tif source=Therapure - IP Security Agreement #page13.tif	

**INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This Intellectual Property Security Agreement is entered into as of the 20<sup>th</sup> day of November, 2015 by and among **MIDCAP FINANCIAL TRUST**, a Delaware statutory trust (“**Agent**”), and **THERAPURE BIOPHARMA INC.**, a corporation formed under the laws of the Province of Ontario (“**Grantor**”).

RECITALS

A. The Lenders (as defined below) have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “**Credit Extensions**”) in the amounts and manner set forth in that certain Credit and Security Agreement by and among Agent, the financial institutions party thereto from time to time (collectively, the “**Lenders**”) and Grantor, dated as the date hereof (as the same may be amended, modified or supplemented from time to time, the “**Credit Agreement**”; capitalized terms used herein are used as defined in the Credit Agreement). The Lenders are willing to make the Credit Extensions to Grantor, but only upon the condition, among others, that Grantor shall grant to Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor under the Credit Agreement.

B. Pursuant to the terms of the Credit Agreement, Grantor has granted to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral (as specifically defined in the Credit Agreement).

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Credit Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Credit Agreement, Grantor grants and pledges to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “**Intellectual Property Collateral**”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “**Copyrights**”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “**Mask Works**”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

This security interest is granted in conjunction with the security interest granted to Agent, for the ratable benefit of the Lenders, under the Credit Agreement. The rights and remedies of Agent with respect to the security interest granted hereby are in addition to those set forth in the Credit Agreement and the other Financing Documents, and those which are now or hereafter available to Agent as a matter of law or equity. Each right, power and remedy of Agent provided for herein or in the Credit Agreement or any of the Financing Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Credit Agreement or any of the other Financing Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Agent, of any or all other rights, powers or remedies.


The provisions of the Credit Agreement regarding choice of law, jurisdiction, venue and jury trial waiver are incorporated herein and shall govern this Intellectual Property Security Agreement.

*[Remainder of page intentionally blank; signature page follows.]*

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

**THERAPURE BIOPHARMA INC.**

By:  (SEAL)  
Name: Nick Green  
Title: CEO

Address of Grantor:  
2585 Meadowpine Boulevard  
Mississauga, Ontario, Canada, L5N 8H9  
Attn: CEO

US INTELLECTUAL PROPERTY  
SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 005674 FRAME: 0570**

AGENT:

**MIDCAP FINANCIAL TRUST**

By: Apollo Capital Management, L.P.,  
its investment manager

By: Apollo Capital Management GP, LLC,  
its general partner

By:  (SEAL)  
Name: Maurice Amsellem  
Title: Authorized Signatory

Address of Agent:

MidCap Financial Trust  
c/o MidCap Financial Services, LLC, as servicer  
7255 Woodmont Ave, Suite 200  
Bethesda, MD 20814  
Attn: Account Manager for Therapure  
transaction

US INTELLECTUAL PROPERTY  
SECURITY AGREEMENT  
SIGNATURE PAGE

**TRADEMARK**  
**REEL: 005674 FRAME: 0571**

N/A

**EXHIBIT A**

Copyrights

EXHIBIT B

Patents

INTELLECTUAL PROPERTY (REGISTRATIONS AND APPLICATIONS)							
Borrower that is Owner of IP Therapure Biopharma Inc. ("TBI")	Name / Identifier of IP	Country	Type of IP	Registration/ Publication or Application Number	Filing Date	Expiration Date	
TBI	Antibody against CD163	US	Patent	62/201,349	08/05/2015	N/A	
TBI	Blood Cell Production via Activation of CD163 (title amended by EPO)	DE	Patent	1372716	03/26/2002	03/25/2022	
TBI	Blood Cell Production via Activation of CD163 (title amended by EPO)	ES	Patent	1372716	03/26/2002	03/25/2022	
TBI	Blood Cell Production via Activation of CD163 (title amended by EPO)	FR	Patent	1372716	03/26/2002	03/25/2022	
TBI	Blood Cell Production via Activation of CD163 (title amended by EPO)	GB	Patent	1372716	03/26/2002	03/25/2022	
TBI	Blood Cell Production via Activation of CD163 (title amended by EPO)	IT	Patent	1372716	03/26/2002	03/25/2022	
TBI	Blood Cell Production via Activation of the Hemoglobin Scavenger Receptor	CA	Patent	2,441,566	03/26/2002	03/26/2022	
TBI	Blood Cell Production via Activation of the Hemoglobin Scavenger Receptor	CN	Patent	ZL02801429.4	03/26/2002	03/26/2022	
TBI	Blood Cell Production via Activation of the Hemoglobin Scavenger Receptor	JP	Patent	4326803	03/26/2002	03/26/2022	
TBI	Blood Cell Production via Activation of the Hemoglobin Scavenger Receptor	KR	Patent	938625	03/26/2002	03/26/2022	
TBI	Blood Cell Production via Activation of the Hemoglobin Scavenger Receptor	SG	Patent	93350	03/26/2002	03/26/2022	
TBI	Blood Cell Production via Activation of the Hemoglobin Scavenger Receptor	US	Patent	7,524,500	09/24/2003	06/06/2022	
TBI	Blood Cell Production via Activation of the Hemoglobin Scavenger Receptor	US	Patent	6,361,998	06/25/1999	06/25/2019	
TBI	Blood Cell Production via Activation of the Hemoglobin Scavenger Receptor	ZA	Patent	2002/9437	03/26/2002	03/26/2022	



**INTELLECTUAL PROPERTY REGISTRATIONS AND APPLICATIONS**

<b>Borrower that is Owner of IP Therapure Biopharma Inc. ("TBI")</b>	<b>Name / Identifier of IP</b>	<b>Country</b>	<b>Type of IP</b>	<b>Registration/ Publication or Application Number</b>	<b>Filing Date</b>	<b>Expiration Date</b>
TBI	Hemoglobin and antibody-drug conjugates for the treatment of Ebola infection	US	Patent	62/081,163	11/18/2014	N/A
TBI	Hemoglobin-antioxidant conjugates	CA	Patent	2,366,833	03/20/2000	04/30/2019
TBI	Hemoglobin-antioxidant conjugates	DE	Patent	1163010	03/20/2000	04/30/2019
TBI	Hemoglobin-antioxidant conjugates	ES	Patent	1163010	03/20/2000	04/30/2019
TBI	Hemoglobin-antioxidant conjugates	FR	Patent	1163010	03/20/2000	04/30/2019
TBI	Hemoglobin-antioxidant conjugates	GB	Patent	1163010	03/20/2000	04/30/2019
TBI	Hemoglobin-antioxidant conjugates	IT	Patent	1163010	03/20/2000	04/30/2019
TBI	Hemoglobin-antioxidant conjugates	JP	Patent	4739530	03/20/2000	04/30/2019
TBI	Hemoglobin-antioxidant conjugates	US	Patent	6,974,794	01/08/2002	04/30/2019
TBI	Hemoglobin-haptoglobin complexes	CA	Patent	2326720	04/30/1999	04/30/2019
TBI	Hemoglobin-haptoglobin complexes	EP	Patent	99919005.1	04/30/1999	04/30/2019
TBI	Hemoglobin-haptoglobin complexes	JP	Patent	4406169	04/30/1999	04/30/2019
TBI	Hemoglobin-polysaccharide conjugates	CA	Patent	2326715	03/25/1999	03/25/2019
TBI	Hemoglobin-polysaccharide conjugates	CN	Patent	ZL99806176.X	03/25/1999	03/25/2019
TBI	Hemoglobin-polysaccharide conjugates	DE	Patent	1066057	03/25/1999	03/25/2019
TBI	Hemoglobin-polysaccharide conjugates	ES	Patent	1066057	03/25/1999	03/25/2019
TBI	Hemoglobin-polysaccharide conjugates	FR	Patent	1066057	03/25/1999	03/25/2019
TBI	Hemoglobin-polysaccharide conjugates	GB	Patent	1066057	03/25/1999	03/25/2019
TBI	Hemoglobin-polysaccharide conjugates	IT	Patent	1066057	03/25/1999	03/25/2019
TBI	Hemoglobin-polysaccharide conjugates	JP	Patent	4674289	03/25/1999	03/25/2019
TBI	Hemoglobin-polysaccharide conjugates	RU	Patent	2225222	03/25/1999	03/25/2019
TBI	Hemoglobin-polysaccharide conjugates	US	Patent	6,500,930	03/26/1999	03/25/2019
TBI	Improved Methods of Engraftment	CA	Patent	2,805,972	02/15/2013	02/15/2033
TBI	Isolation of Human Plasma or Serum Proteins	AT	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	AU	Patent	2012202835	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	AU	Patent	2015200328	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	AU	Patent	2005252296	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	AU	Patent	2009238344	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	BE	Patent	1765866	06/07/2005	06/07/2025

**INTELLECTUAL PROPERTY REGISTRATIONS AND APPLICATIONS**

<b>Borrower that is Owner of IP Therapure Biopharma Inc. ("TBI")</b>	<b>Name / Identifier of IP</b>	<b>Country</b>	<b>Type of IP</b>	<b>Registration/ Publication or Application Number</b>	<b>Filing Date</b>	<b>Expiration Date</b>
TBI	Isolation of Human Plasma or Serum Proteins	BR	Patent	PI0511906-5	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	CH	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	CN	Patent	ZL200580018504.5	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	CZ	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	DE	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	DK	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	EP	Patent	10184552.7	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	EP	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	ES	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	FI	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	FR	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	GB	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	HU	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	IE	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	IN	Patent	263494	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	IT	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	NL	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	PL	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	PT	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	RO	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	SE	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	SK	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	TR	Patent	1765866	06/07/2005	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	US	Patent	US 2007-0299251	07/13/2007	06/07/2025
TBI	Isolation of Human Plasma or Serum Proteins	US	Patent	14/688,906	04/16/2015	06/07/2025
TBI	Method for the Selective Expansion of Lymphocytes by in vitro Cultivation	US	Patent	6,194,207	01/30/1998	01/30/2018
TBI	Method of Reducing a Shift Base	US	Patent	5,847,110	08/15/1997	08/15/2017
TBI	Methods and Compositions for the Treatment of Erdheim-Chester Disease	US	Patent	14/928,528	10/30/2015	10/30/2035

**INTELLECTUAL PROPERTY REGISTRATIONS AND APPLICATIONS**

<b>Borrower that is Owner of IP Therapeutic Biopharma Inc. ("TBI")</b>	<b>Name / Identifier of IP</b>	<b>Country</b>	<b>Type of IP</b>	<b>Registration/ Publication or Application Number</b>	<b>Filing Date</b>	<b>Expiration Date</b>
TBI	Methods and Compositions for the Treatment of Erdheim-Chester Disease	US	Patent	62/199,529	7/31/2015	7/31/2016
TBI	Methods for the production of TCR Gamma Delta T Cells	CA	Patent	2349629	11/04/1999	11/04/2019
TBI	Methods for the production of TCR Gamma Delta T Cells	DE	Patent	1127107	11/04/1999	11/04/2019
TBI	Methods for the production of TCR Gamma Delta T Cells	ES	Patent	1127107	11/04/1999	11/04/2019
TBI	Methods for the production of TCR Gamma Delta T Cells	FR	Patent	1127107	11/04/1999	11/04/2019
TBI	Methods for the production of TCR Gamma Delta T Cells	GB	Patent	1127107	11/04/1999	11/04/2019
TBI	Methods for the production of TCR Gamma Delta T Cells	IT	Patent	1127107	11/04/1999	11/04/2019
TBI	Methods for the production of TCR Gamma Delta T Cells	JP	Patent	4435985	11/04/1999	11/04/2019
TBI	Methods for the production of TCR Gamma Delta T Cells	US	Patent	6,537,812	07/30/2001	11/04/2019
TBI	Modified Polysaccharides Exhibiting Altered Biological Recognition	AU	Patent	761784	12/09/1998	03/09/2018
TBI	Modified Polysaccharides Exhibiting Altered Biological Recognition	CA	Patent	2314716	12/09/1998	03/09/2018
TBI	Modified Polysaccharides Exhibiting Altered Biological Recognition	CH	Patent	1037642	12/09/1998	03/09/2018
TBI	Modified Polysaccharides Exhibiting Altered Biological Recognition	DE	Patent	1037642	12/09/1998	03/09/2018
TBI	Modified Polysaccharides Exhibiting Altered Biological Recognition	ES	Patent	1037642	12/09/1998	03/09/2018
TBI	Modified Polysaccharides Exhibiting Altered Biological Recognition	FR	Patent	1037642	12/09/1998	03/09/2018
TBI	Modified Polysaccharides Exhibiting Altered Biological Recognition	GB	Patent	1037642	12/09/1998	03/09/2018
TBI	Modified Polysaccharides Exhibiting Altered Biological Recognition	GR	Patent	1037642	12/09/1998	03/09/2018
TBI	Modified Polysaccharides Exhibiting Altered Biological Recognition	IT	Patent	1037642	12/09/1998	03/09/2018
TBI	Modified Polysaccharides Exhibiting Altered Biological Recognition	JP	Patent	4435412	12/09/1998	03/09/2018

**INTELLECTUAL PROPERTY REGISTRATIONS AND APPLICATIONS**

<b>Borrower that is Owner of IP Therapure Biopharma Inc. ("TBI")</b>	<b>Name / Identifier of IP</b>	<b>Country</b>	<b>Type of IP</b>	<b>Registration/ Publication or Application Number</b>	<b>Filing Date</b>	<b>Expiration Date</b>
TBI	Modified Polysaccharides Exhibiting Altered Biological Recognition	US	Patent	6,780,852	12/09/1998	03/09/2018
TBI	Modified Polysaccharides Exhibiting Altered Biological Recognition	US	Patent	6,479,468	12/09/1998	03/09/2018
TBI	Polysaccharide-Protein Conjugates Reversibly Coupled Via Imine Bonds	CA	Patent	2,728,000	06/26/2009	03/09/2018
TBI	Polysaccharide-Protein Conjugates Reversibly Coupled Via Imine Bonds	EP	Patent	09768675.2	06/26/2009	03/09/2018
TBI	Polysaccharide-Protein Conjugates Reversibly Coupled Via Imine Bonds	US	Patent	US 2015-0010494	09/22/2014	03/09/2018
TBI	Polysaccharide-Protein Conjugates Reversibly Coupled Via Imine Bonds	US	Patent	8,840,877	12/15/2010	03/09/2018
TBI	Production of TCR Gamma Delta T Cells	CA	Patent	2,405,050	04/03/2001	04/03/2021
TBI	Production of TCR Gamma Delta T Cells	DE	Patent	1268746	04/03/2001	04/03/2021
TBI	Production of TCR Gamma Delta T Cells	ES	Patent	1268746	04/03/2001	04/03/2021
TBI	Production of TCR Gamma Delta T Cells	FR	Patent	1268746	04/03/2001	04/03/2021
TBI	Production of TCR Gamma Delta T Cells	GB	Patent	1268746	04/03/2001	04/03/2021
TBI	Production of TCR Gamma Delta T Cells	IT	Patent	1268746	04/03/2001	04/03/2021
TBI	Production of TCR Gamma Delta T Cells	JP	Patent	4982645	04/03/2001	04/03/2021
TBI	Protein-Protein Interactions	US	Patent	62/168,547	05/29/2015	N/A
TBI	Targeted delivery of anti-viral compounds through hemoglobin bioconjugation	CA	Patent	2,566,874	05/17/2004	05/17/2024
TBI	Targeted delivery of anti-viral compounds through hemoglobin bioconjugation	EP	Patent	04733284.6	05/17/2004	05/17/2024
TBI	Targeted delivery of anti-viral compounds through hemoglobin bioconjugation	US	Patent	US 2012-0213732	02/17/2012	05/17/2024
TBI	Targeted delivery of anti-viral compounds through hemoglobin bioconjugation	US	Patent	6,479,637	04/30/1999	04/30/2019
TBI	Targeted Drug Delivery for Cancer	US	Patent	62/182,469	06/20/2015	N/A

EXHIBIT C

Trademarks

INTELLECTUAL PROPERTY (REGISTRATIONS AND APPLICATIONS)						
Borrower that is Owner of IP Therapure Biopharma Inc. ("TBI")	Name / Identifier of IP	Country	Type of IP	Registration/ Publication or Application Number	Filing Date	Expiration Date
TBI	DAKANSUMIN	AU	TM	1700384	10/30/2014	
TBI	DAKANSUMIN	CA	TM	1,700,384	10/30/2014	
TBI	DAKANSUMIN	CN	TM	16846205	10/30/2014	
TBI	DAKANSUMIN	EP	TM	013981972	10/30/2014	
TBI	DAKANSUMIN	EP	TM	013981972	10/30/2014	
TBI	DAKANSUMIN	JP	TM	2015-041628	10/30/2014	
TBI	DAKANSUMIN	KR	TM	40-2015-32448	10/30/2014	
TBI	DAKANSUMIN	SG	TM	40201507005U	10/30/2014	
TBI	DAKANSUMIN	US	TM	86/607,617	10/30/2014	
TBI	DAKANSUMIN	ZA	TM	2015/10985	10/30/2014	
TBI	PLASMACAP	CA	TM	1638988	08/09/2013	
TBI	PLASMACAP	CN	TM	13742703	12/17/2013	
TBI	PLASMACAP	EP	TM	12072518	08/16/2013	
TBI	PLASMACAP	JP	TM	5695882	12/17/2013	
TBI	PLASMACAP	US	TM	86/039,785	08/16/2013	
TBI	PLASMACAP EBA	CA	TM	1632165	06/21/2013	
TBI	PLASMACAP EBA	US	TM	86/019,802	07/25/2013	
TBI	PLASMACAP EBA & Design	CA	TM	1632163	06/21/2013	
TBI	PLASMACAP EBA & Design	CN	TM	13742702	12/17/2013	
TBI	PLASMACAP EBA & Design	EP	TM	12061891	08/13/2013	
TBI	PLASMACAP EBA & Design	JP	TM	5695883	12/17/2013	
TBI	PLASMACAP EBA & Design	US	TM	86/019,797	07/25/2013	
TBI	THERAPURE BIOLOGICS	CA	TM	1706644	12/10/2014	
TBI	THERAPURE BIOLOGICS	US	TM	86/655,354	06/08/2015	
TBI	THERAPURE BIOLOGICS & DESIGN	CA	TM	1706649	12/10/2014	
TBI	THERAPURE BIOLOGICS & DESIGN	US	TM	86/655,356	06/08/2015	
TBI	THERAPURE BIOPHARMA	CA	TM	803323	07/22/2008	
TBI	THERAPURE BIOPHARMA	CN	TM	7179712	01/22/2009	
TBI	THERAPURE BIOPHARMA	CN	TM	7179711	01/22/2009	
TBI	THERAPURE BIOPHARMA	CN	TM	7179710	01/22/2009	
TBI	THERAPURE BIOPHARMA	EP	TM	7529456	01/16/2009	
TBI	THERAPURE BIOPHARMA	HK	TM	301273536	01/16/2009	

**INTELLECTUAL PROPERTY REGISTRATIONS AND APPLICATIONS**

<b>Borrower that is Owner of IP Therapure Biopharma Inc. ("TBI")</b>	<b>Name / Identifier of IP</b>	<b>Country</b>	<b>Type of IP</b>	<b>Registration/ Publication or Application Number</b>	<b>Filing Date</b>	<b>Expiration Date</b>
TBI	THERAPURE BIOPHARMA	IL	TM	217881	01/21/2009	
TBI	THERAPURE BIOPHARMA	IL	TM	217894	01/21/2009	
TBI	THERAPURE BIOPHARMA	IL	TM	217895	01/21/2009	
TBI	THERAPURE BIOPHARMA	IN	TM	1776907	01/22/2009	
TBI	THERAPURE BIOPHARMA	IN	TM	1776906	01/22/2009	
TBI	THERAPURE BIOPHARMA	IN	TM	1776908	01/22/2009	
TBI	THERAPURE BIOPHARMA	JP	TM	5379521	01/20/2009	
TBI	THERAPURE BIOPHARMA	TW	TM	1379279	01/22/2009	
TBI	THERAPURE BIOPHARMA	US	TM	4381498	08/15/2008	
TBI	THERAPURE BIOPHARMA INC. & Design	CA	TM	849790	05/02/2012	

EXHIBIT D  
Mask Works

N/A

48894613-1